JP7097070B2 - クロライドチャネルの標的発現及びその使用方法 - Google Patents

クロライドチャネルの標的発現及びその使用方法 Download PDF

Info

Publication number
JP7097070B2
JP7097070B2 JP2018536695A JP2018536695A JP7097070B2 JP 7097070 B2 JP7097070 B2 JP 7097070B2 JP 2018536695 A JP2018536695 A JP 2018536695A JP 2018536695 A JP2018536695 A JP 2018536695A JP 7097070 B2 JP7097070 B2 JP 7097070B2
Authority
JP
Japan
Prior art keywords
vector
subunit
cells
promoter
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533976A (ja
JP2018533976A5 (enExample
Inventor
グリフィス ロジャー トーマス，
ショーナリア ジミー フレージャー，
Original Assignee
ゴレイニ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゴレイニ インコーポレイテッド filed Critical ゴレイニ インコーポレイテッド
Publication of JP2018533976A publication Critical patent/JP2018533976A/ja
Publication of JP2018533976A5 publication Critical patent/JP2018533976A5/ja
Application granted granted Critical
Publication of JP7097070B2 publication Critical patent/JP7097070B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018536695A 2015-10-01 2016-09-28 クロライドチャネルの標的発現及びその使用方法 Active JP7097070B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562235920P 2015-10-01 2015-10-01
US201562235914P 2015-10-01 2015-10-01
US62/235,920 2015-10-01
US62/235,914 2015-10-01
US201662303907P 2016-03-04 2016-03-04
US62/303,907 2016-03-04
US201662378509P 2016-08-23 2016-08-23
US62/378,509 2016-08-23
PCT/US2016/054199 WO2017058926A1 (en) 2015-10-01 2016-09-28 Targeted expression of chloride channels and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018533976A JP2018533976A (ja) 2018-11-22
JP2018533976A5 JP2018533976A5 (enExample) 2019-10-31
JP7097070B2 true JP7097070B2 (ja) 2022-07-07

Family

ID=58427328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536695A Active JP7097070B2 (ja) 2015-10-01 2016-09-28 クロライドチャネルの標的発現及びその使用方法

Country Status (11)

Country Link
US (1) US11407812B2 (enExample)
EP (1) EP3355938B1 (enExample)
JP (1) JP7097070B2 (enExample)
KR (2) KR20180072713A (enExample)
CN (1) CN108289965A (enExample)
AU (1) AU2016332847B2 (enExample)
BR (1) BR112018006480A2 (enExample)
CA (1) CA2999279A1 (enExample)
HK (1) HK1252915A1 (enExample)
SG (1) SG10201912703PA (enExample)
WO (1) WO2017058926A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3880179A2 (en) * 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
CN110679548B (zh) * 2019-10-24 2021-11-30 南方医科大学南方医院 一种自闭症小鼠模型的构建方法
CN111759857A (zh) * 2020-06-30 2020-10-13 宁波市微循环与莨菪类药研究所 Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用
CN115480485B (zh) * 2022-09-14 2024-09-10 南开大学 一种基于数据驱动模型的软镜扭转运动安全控制方法
GB202401492D0 (en) 2024-02-05 2024-03-20 Ucl Business Ltd Chloride channels and uses thereof
CN119331917B (zh) * 2024-10-28 2025-10-17 北京爱思益普生物科技股份有限公司 能够表达GlyR α1/β型GlyR的细胞株及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500126A (ja) 2000-06-20 2004-01-08 バイオノミックス　リミテッド てんかんに関係する突然変異
US20080289058A1 (en) 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
JP2012504966A (ja) 2008-10-09 2012-03-01 ハワード ヒューズ メディカル インスティチュート 新規なキメラリガンド開口型イオンチャネルおよびその使用方法
WO2014093251A1 (en) 2012-12-10 2014-06-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Engineered receptors and their use
JP2018531926A (ja) 2015-09-17 2018-11-01 コーダ バイオセラピューティクス， インコーポレイテッド 神経学的障害を処置するための組成物および方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644643A (en) * 1969-10-13 1972-02-22 Unimed Inc Method of reducing intraocular pressure using glycine
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5527703A (en) 1994-05-25 1996-06-18 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2002066606A2 (en) * 2001-02-16 2002-08-29 Bristol-Myers Squibb Company Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, hgra4, and splice variant thereof
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US8298818B2 (en) * 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
DK2061891T3 (da) 2006-08-24 2012-07-23 Virovek Inc Ekspression i insektceller af gener med overlappende åbne læserammer, fremgangsmåder og sammensætninger hertil
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
EP2283038A1 (en) * 2008-04-30 2011-02-16 Dublin City University Compositions and methods for expressing in-frame multimeric proteins
US20130184318A1 (en) 2010-04-30 2013-07-18 The Regents Of The University Of California Modulating compliance of trabecular meshwork
WO2012155091A1 (en) 2011-05-11 2012-11-15 Kirax Corporation Package for improved treatment of conditions
EP2877213B1 (en) * 2012-07-25 2020-12-02 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
EP2692868A1 (en) * 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
WO2015106005A1 (en) 2014-01-08 2015-07-16 Circuit Therapeutics, Inc. Method for therapeutic management of ocular hypertension
AU2015237140A1 (en) 2014-03-27 2016-10-13 Circuit Therapeutics, Inc. System and method for therapeutic management of cough
JP2017531652A (ja) 2014-10-06 2017-10-26 アルスロジェン ビー．ブイ．Ａｒｔｈｒｏｇｅｎ Ｂ．Ｖ． Ａａｖに基づく遺伝子治療
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
KR20180134846A (ko) 2016-04-21 2018-12-19 바이로베크 인코포레이티드 곤충 세포에서의 aav 생산, 및 이를 위한 방법 및 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500126A (ja) 2000-06-20 2004-01-08 バイオノミックス　リミテッド てんかんに関係する突然変異
US20080289058A1 (en) 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
JP2012504966A (ja) 2008-10-09 2012-03-01 ハワード ヒューズ メディカル インスティチュート 新規なキメラリガンド開口型イオンチャネルおよびその使用方法
WO2014093251A1 (en) 2012-12-10 2014-06-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Engineered receptors and their use
JP2018531926A (ja) 2015-09-17 2018-11-01 コーダ バイオセラピューティクス， インコーポレイテッド 神経学的障害を処置するための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Journal of Biological Chemistry，2013年，Vol. 288, No. 29，pp. 21029-21042
The Journal of Pharmacology and Experimental Therapeutics，2002年，Vol. 300, No. 2，pp. 526-534

Also Published As

Publication number Publication date
AU2016332847B2 (en) 2023-08-10
KR20180072713A (ko) 2018-06-29
AU2016332847A1 (en) 2018-04-19
BR112018006480A2 (pt) 2018-10-09
CN108289965A (zh) 2018-07-17
EP3355938A4 (en) 2019-03-06
EP3355938B1 (en) 2024-02-07
EP3355938A1 (en) 2018-08-08
KR20250012721A (ko) 2025-01-24
HK1252915A1 (zh) 2019-06-06
AU2016332847A2 (en) 2023-08-03
SG10201912703PA (en) 2020-02-27
JP2018533976A (ja) 2018-11-22
US11407812B2 (en) 2022-08-09
US20190010210A1 (en) 2019-01-10
CA2999279A1 (en) 2017-04-06
WO2017058926A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
JP7097070B2 (ja) クロライドチャネルの標的発現及びその使用方法
JP7057281B2 (ja) 眼疾患のための遺伝子療法
JP5897549B2 (ja) レーバー先天性黒内障１（ＬＣＡ１）を処置するためのｒＡＡＶ−グアニル酸シクラーゼ組成物および方法
JP7097398B2 (ja) ミオシリン（ｍｙｏｃ）緑内障を処置するためのアデノ随伴ウイルスベクター
ES2871527T3 (es) Virión de virus adenoasociado para usar en el tratamiento de la epilepsia
TW201905200A (zh) 調節多核苷酸
US11858969B2 (en) Engineered light-sensitive proteins
CN105980569A (zh) 重组aav-crumbs同源物组合物及治疗lca-8和进行性rp的方法
JP6949867B2 (ja) 神経の過剰興奮を治療するための方法および組成物
TW201902911A (zh) 用於治療ｃｎｇｂ１關聯之視網膜色素病變的基因療法
JP2023116709A (ja) 眼疾患のための遺伝子療法
WO2023116745A1 (zh) 优化的cyp4v2基因及其用途
JP7334996B2 (ja) グルコーストランスポーター１発現用アデノ随伴ウイルスベクター
CN115006534B (zh) 钾离子通道Kir4.1抑制剂治疗抑郁症的用途和药物组合物
KR20190028389A (ko) 디스펄린병증의 치료를 위한 절단형 디스펄린
US20240216536A1 (en) Secreted ube3a for treatment of neurological disorders
JP2025508336A (ja) Ｔｐｋを発現する組換えウイルスおよびアルツハイマー病の処置におけるその使用
JP7745890B2 (ja) 改変光受容クロライドチャネル
US20220387627A1 (en) Vectors and gene therapy for treating cornelia de lange syndrome
WO2025175135A1 (en) Modifying neurons to treat or prevent parkinson's disease
US20220364118A1 (en) Targeting deltafosb for treatment of dyskinesia
Murillo Bartolomé Effects of GluN3A silencing in Huntington's disease and systematic mapping of its expression in the mouse forebrain
JP2025523953A (ja) 肢帯型筋ジストロフィーのためのａｕｆ１遺伝子療法
KR20220152550A (ko) Nmnat1-연관 망막 변성의 유전자 치료법
Levin Muscle Lim Protein in naïve and injured neurons

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220620

R150 Certificate of patent or registration of utility model

Ref document number: 7097070

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250